REG - BkofA Merrill Lynch Avadel Pharma plc - Form 8.3-Avadel Pharmaceuticals plc
09/12/2025 12:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251209:nRSI8555Ka&default-theme=true
RNS Number : 8555K Bank of America Merrill Lynch 09 December 2025
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH
TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1%
OR MORE
1. KEY INFORMATION
(a) Full name of discloser Bank of America Corporation
(b) Owner or controller of interests and short positions disclosed, if
different from 1(a)
The naming of nominee or vehicle companies is insufficient. For a trust, the
trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this AVADEL PHARMACEUTICALS PLC
form relates
Use a separate form for each offeror/offeree
(d) If an exempt fund manager connected with an offeror/offeree, state
this and specify identity of offeror/offeree (Note 1)
(e) Date position held/dealing undertaken 08/12/2025
For an opening position disclosure, state the latest practicable date prior to
the disclosure
(f) In addition to the company in 1(c) above, is the discloser also No
making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class
of relevant securities of the offeror or offeree named in 1(c), copy table 2
for each additional class of relevant security.
Interests and short positions in the relevant securities of the offeror or
offeree to which the disclosure relates following the dealing (if any)
(Note 2)
Class of relevant security 0.01 ordinary shares
(Note 3)
Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled 823,817 0.846% 349,386 0.359%
(2) Cash-settled derivatives 273,012 0.280% 686,567 0.705%
(3) Stock-settled derivatives (including options) and agreements to 0 0.000% 0 0.000%
purchase/ sell
Total 1,096,829 1.126% 1,035,953 1.064%
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any
open stock-settled derivative positions (including traded options), or
agreements to purchase or sell relevant securities, should be given on a
Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE
DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities
of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as
appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant Purchase/sale Number of Price per unit
security
securities (Note 5)
USD 0.01 common Purchase 55 21.31 USD
USD 0.01 common Purchase 326 21.32 USD
USD 0.01 common Purchase 12 21.325 USD
USD 0.01 common Purchase 6 21.326667 USD
USD 0.01 common Purchase 20 21.3285 USD
USD 0.01 common Purchase 374 21.33 USD
USD 0.01 common Purchase 22 21.330455 USD
USD 0.01 common Purchase 16 21.330625 USD
USD 0.01 common Purchase 22 21.331819 USD
USD 0.01 common Purchase 20 21.332 USD
USD 0.01 common Purchase 17 21.332353 USD
USD 0.01 common Purchase 24 21.3325 USD
USD 0.01 common Purchase 27 21.332593 USD
USD 0.01 common Purchase 26 21.332693 USD
USD 0.01 common Purchase 27 21.333704 USD
USD 0.01 common Purchase 28 21.333929 USD
USD 0.01 common Purchase 25 21.334 USD
USD 0.01 common Purchase 24 21.334167 USD
USD 0.01 common Purchase 28 21.334286 USD
USD 0.01 common Purchase 22 21.334546 USD
USD 0.01 common Purchase 28 21.334643 USD
USD 0.01 common Purchase 29 21.334828 USD
USD 0.01 common Purchase 18 21.335 USD
USD 0.01 common Purchase 20 21.3355 USD
USD 0.01 common Purchase 29 21.335518 USD
USD 0.01 common Purchase 25 21.3356 USD
USD 0.01 common Purchase 19 21.33579 USD
USD 0.01 common Purchase 22 21.33591 USD
USD 0.01 common Purchase 21 21.336191 USD
USD 0.01 common Purchase 20 21.337 USD
USD 0.01 common Purchase 32 21.339063 USD
USD 0.01 common Purchase 27 21.33963 USD
USD 0.01 common Purchase 203 21.34 USD
USD 0.01 common Purchase 26 21.341154 USD
USD 0.01 common Purchase 7 21.35 USD
USD 0.01 common Purchase 16 21.35 USD
USD 0.01 common Purchase 200 21.3182 USD
Class of relevant Purchase/sale Number of Price per unit
security
securities (Note 5)
USD 0.01 common Sale 3 21.306667 USD
USD 0.01 common Sale 480 21.31 USD
USD 0.01 common Sale 62 21.315 USD
USD 0.01 common Sale 56 21.315715 USD
USD 0.01 common Sale 25 21.316 USD
USD 0.01 common Sale 12 21.316667 USD
USD 0.01 common Sale 1,194 21.32 USD
USD 0.01 common Sale 302 21.325 USD
USD 0.01 common Sale 9 21.325556 USD
USD 0.01 common Sale 21 21.325715 USD
USD 0.01 common Sale 35 21.326 USD
USD 0.01 common Sale 12 21.326667 USD
USD 0.01 common Sale 1,499 21.33 USD
USD 0.01 common Sale 24 21.3325 USD
USD 0.01 common Sale 27 21.332593 USD
USD 0.01 common Sale 26 21.332693 USD
USD 0.01 common Sale 28 21.333929 USD
USD 0.01 common Sale 25 21.334 USD
USD 0.01 common Sale 24 21.334167 USD
USD 0.01 common Sale 22 21.334546 USD
USD 0.01 common Sale 29 21.334828 USD
USD 0.01 common Sale 344 21.335 USD
USD 0.01 common Sale 37 21.335136 USD
USD 0.01 common Sale 50 21.3352 USD
USD 0.01 common Sale 38 21.335264 USD
USD 0.01 common Sale 15 21.335334 USD
USD 0.01 common Sale 13 21.335385 USD
USD 0.01 common Sale 33 21.335455 USD
USD 0.01 common Sale 20 21.3355 USD
USD 0.01 common Sale 29 21.335518 USD
USD 0.01 common Sale 9 21.335556 USD
USD 0.01 common Sale 25 21.3356 USD
USD 0.01 common Sale 14 21.335715 USD
USD 0.01 common Sale 35 21.336 USD
USD 0.01 common Sale 21 21.336191 USD
USD 0.01 common Sale 48 21.336667 USD
USD 0.01 common Sale 2,429 21.34 USD
USD 0.01 common Sale 271 21.35 USD
USD 0.01 common Sale 132,090 21.32 USD
USD 0.01 common Sale 32,100 21.3305 USD
(b) Cash-settled derivative transactions
Class of Product Nature of dealing Number of Price
relevant description e.g. opening/ closing a long/ short position, increasing/ reducing a long/ reference per unit
security e.g. CFD short position securities (Note 5)
(Note 6)
USD
USD 0.01 common Swaps Reducing a long position 200 21.3185 USD
USD 0.01 common Swaps Reducing a short position 32,100 21.328 USD
USD 0.01 common Swaps Opening a long position 132,088 21.32 USD
(c) Stock-settled derivative transactions (including
options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, purchasing, selling, varying Number Exercise Type Expiry Option
relevant description e.g. call etc. of
price per e.g. date money
security option securities unit American,
paid/
to which European received per unit
option
etc.
relates
(Note 6)
N/A N/A N/A N/A N/A N/A N/A N/A
(ii) Exercise
Class of Product Exercising/ Number of Exercise
relevant description exercised securities price per
security e.g. call against unit
option (Note 5)
N/A N/A N/A N/A N/A
(d) Other dealings (including transactions in respect of
new securities) (Note 3)
Class of Nature of dealing Details Price per unit (if
relevant e.g. subscription, applicable)
security conversion, exercise (Note 5)
N/A N/A N/A N/A
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or
understanding, formal or informal, relating to relevant securities which may
be an inducement to deal or refrain from dealing entered into by the person
making the disclosure and any party to the offer or any person acting in
concert with a party to the offer.
Irrevocable commitments and letters of intent should not be included. If there
are no such agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to
options or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which
any derivative referred to on this form is referenced. If none, this should be
stated.
(c) Attachments
Is a Supplemental Form 8 attached? No
Date of disclosure 09/12/2025
Contact name Kamil Dziedzic
Telephone number +353 86 168 4821
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory
Information Service.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ITPFLFLLFELAIIE
Copyright 2019 Regulatory News Service, all rights reservedRecent news on Avadel Pharmaceuticals
See all newsREG - BlackRock Group Avadel Pharma plc - Form 8.3 - Avadel Pharmaceuticals plc
AnnouncementREG - JPMorgan Sec.Plc Avadel Pharma plc - Form 38.5A (EPT/RI)- Avadel Pharmaceuticals Amend
AnnouncementREG - TIG Advisors, LLC Avadel Pharma plc - Form 8.3 - Avadel Pharmaceuticals plc
AnnouncementREG - Citadel Group Avadel Pharma plc - Form 8.3 - Avadel Pharmaceuticals plc
AnnouncementREG - Geode Capital Mgmnt Avadel Pharma plc - Form 8.3 - Avadel Pharmaceuticals plc
Announcement